Unique "delta lock" structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor

Biochemical and Biophysical Research Communications

Volumn 404, Issue 1, 2011, Pages 434-437

  Ohno, Kazuki ^a   Amano, Yasushi ^a   Kakuta, Hirotoshi ^a   Niimi, Tatsuya ^a   Takakura, Shoji ^a   Orita, Masaya ^a   Miyata, Keiji ^a   Sakashita, Hitoshi ^a   Takeuchi, Makoto ^a   Komuro, Issei ^b   Higaki, Jitsuo ^c   Horiuchi, Masatsugu ^c   Kim Mitsuyama, Shokei ^d   Mori, Yutaka ^e   Morishita, Ryuichi ^b   Yamagishi, Sho ichi ^f  

^a ASTELLAS PHARMA INC   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II type 1 receptor blockers; Docking model; Hypertension; Telmisartan

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; AZILSARTAN; BENZIMIDAZOLE; CANDESARTAN; IRBESARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG STRUCTURE; LIPOPHILICITY; MOLECULAR DOCKING; MOLECULAR INTERACTION; PRIORITY JOURNAL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; CATTLE; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYPERTENSION; MODELS, MOLECULAR; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 78650882616     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.11.139     Document Type: Article

References (18)

1. Blood Pressure Lowering Treatment Trialists' Collaboration Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertens. 2007, 25:951-958.
2. Burnier M., Brunner H.R. Angiotensin II receptor antagonists. Lancet 2000, 355:637-645.
3. de Gasparo M., Catt K.J., Inagami T., et al. Parmacol. Rev. 2000, 52:415-472.
4. 2 receptor: new insights into an old system. Regul. Pept. 2001, 99:175-182.
5. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001, 345:861-869. RENAAL Study Investigators.
6. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771. CHARM Investigators Committees.
7. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 2004, 43:S14-S290. Kidney Disease Outcomes Quality Initiative.
8. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am. J. Kidney Dis. 2007, 49:S12-S154. Kidney Disease Outcomes Quality Initiative.
9. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol. Dial. Transplant. 2004, 19:ii1-ii47. European Best Practice Guidelines Working Group.
10. Nixon R.M., Müller E., Lowy1 A., et al. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int. J. Clin. Pract. 2009, 63:766-775.
11. Lacourcière Y., Krzesinski J.M., White W.B., et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press. Monit. 2004, 9:203-210.
12. Tuccinardi T., Calderone V., Rapposelli S., et al. Proposal of a new binding orientation for non-peptide AT1 antagonists: homology model, docking and 3D-QSAR analysis. J. Med. Chem. 2006, 49:4305-4316.
13. Wacker D., Fenalti G., Brown M.A., et al. Conserved binding mode of human β2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J. Am. Chem. Soc. 2010, 132:11443-11445.
14. 1) receptor: insights into the molecular determinants of Telmisartan binding. Proteins 2006, 65:824-842.
15. Miura S., Fujino M., Hanzawa H., et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J. Biol. Chem. 2006, 281:19288-19295.
16. Wienen W., Entzeroth M., van Meel J.C.A., et al. A review of telmisartan: a novel, long acting angiotensin II-receptor antagonist, long acting angiotensin II-receptor antagonist. Cardiovasc. Drug Rev. 2000, 18:127-154.
17. Kurtz T.W., Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J. Hypertens. 2004, 22:2253-2261.
18. Kakuta H., Sudoh K., Sasamata M., et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int. J. Clin. Pharmacol. Res. 2005, 25:41-46.